Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
"Who might be able to join this trial:
- People who are older than 18 years of age.
- People who have a confirmed diagnosis of Triple Negative Breast Cancer that is either at an advanced (spread) stage and has not yet been treated with systemic (whole-body) therapy, or at an earlier stage with remaining tumour detected after completing chemotherapy containing specific drug types (anthracyclines and taxanes).
- People who have confirmed advanced colorectal (bowel) cancer that has spread, treated with no more than one round of systemic (whole-body) therapy, and who are either having surgery to remove liver tumours or have tumours that a doctor can safely biopsy.
- People who have confirmed advanced high-grade serious ovarian cancer that has either returned (with a life expectancy of at least 12 months), or is at Stage III or IV with remaining disease after chemotherapy, or is considered at high risk of returning.
- People who have a confirmed solid tumour that does not fall into the above categories, where the trial team has determined there is a particular reason to investigate new treatments (confirm with trial site).
- People whose cancer can be safely accessed for a tissue sample through biopsy or surgery.
- People who are in generally good physical condition, able to carry out normal daily activities or light work (this is measured using a standard scale called ECOG, scores 0–1).
- People who are willing and able to give their own signed consent to participate.
Who may not be able to join:
- People with serious problems affecting the liver, kidneys, heart, or other major organs that are likely to limit safe participation in clinical trials.
- People who have cancer that has spread to the brain.
- People who have a condition that affects their ability to understand and agree to participation, such as dementia or severe cognitive impairment.
- People for whom having a biopsy procedure would not be medically safe or suitable.
Important: Always verify eligibility with the trial site directly before applying."
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: David Cescon, MD, Princess Margaret Cancer Centre
Phone: 416-946-2245
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Measure of drug sensitive pPDX to a panel of drugs as a predictor of clinical response in matched host; Rate of results reporting; Rate of pPDX engraftment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.